Latest Insider Transactions at Quest Diagnostics Inc (DGX)
This section provides a real-time view of insider transactions for Quest Diagnostics Inc (DGX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of QUEST DIAGNOSTICS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of QUEST DIAGNOSTICS INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 27
2025
|
Catherine T. Doherty EVP, Regional Businesses |
SELL
Open market or private sale
|
Direct |
824
-1.18%
|
$141,728
$172.61 P/Share
|
|
Feb 27
2025
|
Michael E Prevoznik SVP & General Counsel |
SELL
Open market or private sale
|
Direct |
528
-1.33%
|
$90,816
$172.61 P/Share
|
|
Feb 26
2025
|
Sam Samad Executive Vice President & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
869
-4.13%
|
$148,599
$171.75 P/Share
|
|
Feb 26
2025
|
Catherine T. Doherty EVP, Regional Businesses |
SELL
Payment of exercise price or tax liability
|
Direct |
455
-0.65%
|
$77,805
$171.75 P/Share
|
|
Feb 26
2025
|
Karthik Kuppusamy SVP, Clinical Solutions |
SELL
Payment of exercise price or tax liability
|
Direct |
233
-1.98%
|
$39,843
$171.75 P/Share
|
|
Feb 26
2025
|
Patrick Plewman SVP for Diagnostic Services |
SELL
Payment of exercise price or tax liability
|
Direct |
229
-1.27%
|
$39,159
$171.75 P/Share
|
|
Feb 26
2025
|
Michael E Prevoznik SVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
286
-0.72%
|
$48,906
$171.75 P/Share
|
|
Feb 26
2025
|
J. E. Davis CEO and President |
SELL
Payment of exercise price or tax liability
|
Direct |
2,966
-2.1%
|
$507,186
$171.75 P/Share
|
|
Feb 26
2025
|
Mark E Delaney SVP & Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
214
-3.45%
|
$36,594
$171.75 P/Share
|
|
Feb 26
2025
|
Michael J Deppe SVP, Corp. Controller & CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
88
-0.25%
|
$15,048
$171.75 P/Share
|
|
Feb 20
2025
|
Catherine T. Doherty EVP, Regional Businesses |
SELL
Open market or private sale
|
Direct |
899
-1.26%
|
$152,830
$170.99 P/Share
|
|
Feb 20
2025
|
Michael E Prevoznik SVP & General Counsel |
SELL
Open market or private sale
|
Direct |
604
-1.49%
|
$102,680
$170.99 P/Share
|
|
Feb 19
2025
|
Sam Samad Executive Vice President & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,031
-4.67%
|
$174,239
$169.71 P/Share
|
|
Feb 19
2025
|
Catherine T. Doherty EVP, Regional Businesses |
SELL
Open market or private sale
|
Direct |
535
-0.74%
|
$90,415
$169.71 P/Share
|
|
Feb 19
2025
|
Karthik Kuppusamy SVP, Clinical Solutions |
SELL
Payment of exercise price or tax liability
|
Direct |
287
-2.38%
|
$48,503
$169.71 P/Share
|
|
Feb 19
2025
|
Patrick Plewman SVP for Diagnostic Services |
SELL
Open market or private sale
|
Direct |
320
-1.74%
|
$54,080
$169.71 P/Share
|
|
Feb 19
2025
|
Michael E Prevoznik SVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
374
-0.92%
|
$63,206
$169.71 P/Share
|
|
Feb 19
2025
|
J. E. Davis CEO and President |
SELL
Payment of exercise price or tax liability
|
Direct |
2,936
-2.04%
|
$496,184
$169.71 P/Share
|
|
Feb 19
2025
|
Mark E Delaney SVP & Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
242
-3.76%
|
$40,898
$169.71 P/Share
|
|
Feb 19
2025
|
Michael J Deppe SVP, Corp. Controller & CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
99
-0.28%
|
$16,731
$169.71 P/Share
|
|
Feb 12
2025
|
Sam Samad Executive Vice President & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
4,538
+17.05%
|
-
|
|
Feb 12
2025
|
J. E. Davis CEO and President |
BUY
Grant, award, or other acquisition
|
Direct |
18,149
+11.18%
|
-
|
|
Feb 12
2025
|
Michael J Deppe SVP, Corp. Controller & CAO |
BUY
Grant, award, or other acquisition
|
Direct |
454
+1.27%
|
-
|
|
Feb 12
2025
|
Mark E Delaney SVP & Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,815
+21.99%
|
-
|
|
Feb 12
2025
|
Catherine T. Doherty EVP, Regional Businesses |
BUY
Grant, award, or other acquisition
|
Direct |
3,479
+4.62%
|
-
|
|
Feb 12
2025
|
Karthik Kuppusamy SVP, Clinical Solutions |
BUY
Grant, award, or other acquisition
|
Direct |
2,269
+15.83%
|
-
|
|
Feb 12
2025
|
Patrick Plewman SVP for Diagnostic Services |
BUY
Grant, award, or other acquisition
|
Direct |
2,042
+9.99%
|
-
|
|
Feb 12
2025
|
Michael E Prevoznik SVP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
2,345
+5.43%
|
-
|
|
Feb 05
2025
|
Mark E Delaney SVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
403
-8.02%
|
$66,092
$164.3 P/Share
|
|
Feb 05
2025
|
Vicky B Gregg Director |
SELL
Open market or private sale
|
Direct |
1,250
-6.9%
|
$205,000
$164.57 P/Share
|
|
Jan 29
2025
|
Patrick Plewman SVP for Diagnostic Services |
BUY
Small Acquisition
|
Direct |
57
+0.35%
|
$9,006
$158.04 P/Share
|
|
Jan 29
2025
|
Sam Samad Executive Vice President & CFO |
BUY
Small Acquisition
|
Direct |
35
+0.2%
|
$5,530
$158.04 P/Share
|
|
Jan 29
2025
|
Vicky B Gregg Director |
BUY
Small Acquisition
|
Direct |
72
+0.4%
|
$11,376
$158.04 P/Share
|
|
Jan 29
2025
|
Mark E Delaney SVP & Chief Commercial Officer |
BUY
Small Acquisition
|
Direct |
4
+0.08%
|
$632
$158.03 P/Share
|
|
Jan 29
2025
|
Karthik Kuppusamy SVP, Clinical Solutions |
BUY
Small Acquisition
|
Direct |
12
+0.12%
|
$1,896
$158.03 P/Share
|
|
Nov 29
2024
|
Michael E Prevoznik SVP & General Counsel |
SELL
Open market or private sale
|
Direct |
35,146
-24.8%
|
$5,693,652
$162.7 P/Share
|
|
Nov 29
2024
|
Michael E Prevoznik SVP & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
35,146
+32.31%
|
$3,022,556
$86.63 P/Share
|
|
Nov 27
2024
|
Catherine T. Doherty EVP, Regional Businesses |
SELL
Open market or private sale
|
Direct |
33,103
-17.0%
|
$5,362,686
$162.64 P/Share
|
|
Nov 27
2024
|
Catherine T. Doherty EVP, Regional Businesses |
BUY
Exercise of conversion of derivative security
|
Direct |
33,103
+24.59%
|
$3,409,609
$103.57 P/Share
|
|
Nov 06
2024
|
Michael J Deppe SVP, Corp. Controller & CAO |
SELL
Open market or private sale
|
Direct |
18,755
-6.86%
|
$2,869,515
$153.82 P/Share
|
|
Nov 06
2024
|
Michael J Deppe SVP, Corp. Controller & CAO |
BUY
Exercise of conversion of derivative security
|
Direct |
18,755
+16.2%
|
$1,275,340
$68.84 P/Share
|
|
Oct 28
2024
|
Karthik Kuppusamy SVP, Clinical Solutions |
SELL
Open market or private sale
|
Direct |
1,775
-15.42%
|
$276,900
$156.92 P/Share
|
|
Oct 21
2024
|
Patrick Plewman SVP for Diagnostic Services |
BUY
Small Acquisition
|
Direct |
60
+0.37%
|
$8,940
$149.37 P/Share
|
|
Oct 21
2024
|
Karthik Kuppusamy SVP, Clinical Solutions |
BUY
Small Acquisition
|
Direct |
21
+0.18%
|
$3,129
$149.37 P/Share
|
|
Oct 21
2024
|
Sam Samad Executive Vice President & CFO |
BUY
Small Acquisition
|
Direct |
37
+0.21%
|
$5,513
$149.37 P/Share
|
|
Oct 21
2024
|
Mark E Delaney SVP & Chief Commercial Officer |
BUY
Small Acquisition
|
Direct |
4
+0.08%
|
$596
$149.39 P/Share
|
|
Oct 21
2024
|
Vicky B Gregg Director |
BUY
Small Acquisition
|
Direct |
76
+0.42%
|
$11,324
$149.37 P/Share
|
|
Sep 24
2024
|
Mark A Gardner SVP of Molecular Gen & Oncol |
SELL
Payment of exercise price or tax liability
|
Direct |
120
-2.5%
|
$18,600
$155.7 P/Share
|
|
Aug 29
2024
|
Michael E Prevoznik SVP & General Counsel |
SELL
Open market or private sale
|
Direct |
32,551
-45.83%
|
$5,012,854
$154.97 P/Share
|
|
Aug 29
2024
|
Michael E Prevoznik SVP & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
32,551
+31.43%
|
$3,092,345
$95.8 P/Share
|